

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark VAN ASTEN
Date of last notice	01 May 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	23 June 2020
No. of securities held prior to change	i) 420,000 Shares ii) 50,000 Performance Rights vested on 6 June 2020. iii) 75,000 Listed options (exercisable at \$0.05, expiring on 26 November 2021) iv) 120,000 Listed options (exercisable at \$0.03, expiring on 28 April 2023)
Class	i) Fully Paid Ordinary Shares (Shares) ii) Performance Rights iii) Listed options (exercisable at \$0.05, expiring on 26 November 2021) iv) Listed options (exercisable at \$0.03, expiring on 28 April 2023)
Number acquired	i) 50,000 Shares ii) Nil Performance Rights iii) Nil Listed options (exercisable at \$0.05, expiring on 26 November 2021) iv) Nil Listed options (exercisable at \$0.03, expiring on 28 April 2023)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	<ul style="list-style-type: none"> i) Nil Fully Paid Ordinary Shares ii) 50,000 Performance Rights iii) Nil Listed options (exercisable at \$0.05, expiring on 26 November 2021) iv) Nil Listed options (exercisable at \$0.03, expiring on 28 April 2023)
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ul style="list-style-type: none"> i) Nil per Share ii) N/A Performance Rights iii) N/A Listed options (exercisable at \$0.05, expiring on 26 November 2021) iv) N/A Listed options (exercisable at \$0.03, expiring on 28 April 2023)
No. of securities held after change	<ul style="list-style-type: none"> i) 470,000 Shares ii) 75,000 Listed options (exercisable at \$0.05, expiring on 26 November 2021) iii) 120,000 Listed options (exercisable at \$0.03, expiring on 28 April 2023)
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Vesting of Performance Rights which were issued on 14 June 2018 under Company's LTIP, as approved by Shareholders on 31 May 2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
--	----

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.